- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01994083
A Study of Multiple Oral Doses of IX-01 in Healthy Men
September 2, 2014 updated by: Ixchelsis Limited
A Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of IX-01 in Healthy Male Subjects
The purpose of this study is to investigate the safety and tolerability of IX-01 after multiple doses, and to determine how the body handles IX-01.
Study Overview
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
London, United Kingdom
- Hammersmith Medicines Research (HMR)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- A body mass index (Quetelet index) in the range 18-30
- Total body weight greater than (>)50 kilograms (kg) at screening
- Able to understand the nature of the trial and any hazards of participating in it
- Able to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial
- Participants and their partners must be willing to use adequate forms of contraception and comply with contraception requirements during the trial, and for 4 months after the last dose of medication
- Must not plan to donate sperm or father a child during the trial, and for 4 months after the final dose of medication
Exclusion Criteria:
- Clinically relevant abnormal history, physical findings, electrocardiogram (ECG), or laboratory values at the screening assessment that could interfere with the objectives of the trial or the safety of the participant
- Presence of acute or chronic illness or history of chronic illness sufficient to invalidate participation in the trial or make it unnecessarily hazardous
- Impaired gastrointestinal, endocrine, thyroid, hepatic, cardiovascular, respiratory, haematological, renal or neurological function, diabetes mellitus, coronary heart disease, or history of any psychotic mental illness
- Surgery (for example (e.g.) stomach bypass) or medical condition that might affect absorption, metabolism or elimination of medicines
- Presence or history of severe adverse reaction to any drug
- Use of any prescription or over-the-counter medicine during the 14 days before the first dose of trial medication, or intention to use any medicine during the trial, with the exception of short courses of medication considered by the investigator not to interfere with the safety of the participant or the integrity of the trial data (such as acetaminophen (paracetamol))
- Current use of any herbal remedy or nutritional supplement, or intention to use any such product during the study
- Participation in another clinical trial of a new chemical entity or a prescription medicine within the previous 3 months
- Previous participation in this trial or any other clinical trial of an oxytocin receptor antagonist
- Presence or history of drug or alcohol abuse, or intake of more than 21 units of alcohol weekly or more than 5 cigarettes daily
- Blood pressure and heart rate in supine position at the screening examination outside the ranges 90-130 millimeters of mercury (mm Hg) systolic, 50-90 mm Hg diastolic; heart rate 50-90 beats/minute
- Possibility that the participant will not cooperate with the requirements of the protocol
- Evidence of drug abuse on urine testing
- Positive test for hepatitis B, hepatitis C, Human Immunodeficiency Virus 1(HIV1) or Human Immunodeficiency Virus 2 (HIV2)
- Loss of more than 400 milliliters (mL) blood during the 3 months before the trial, e.g. as a blood donor
- Objection by General Practitioner (GP), on medical grounds, to participant entering trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Administered orally
|
Experimental: IX-01
Up to 4 different dose groups within 50 to 1,200 mg of IX-01 oral aqueous dispersion, administered once daily for 10 days
|
Administered orally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants with One or More Drug Related Adverse Events (AEs) or any Serious AEs
Time Frame: Baseline to Day 20 (Estimated up to 3 weeks)
|
Baseline to Day 20 (Estimated up to 3 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Peak Plasma Concentration (Cmax) of IX-01
Time Frame: Pre-dose to 24 hours post dose on Days 1 and 10
|
Pre-dose to 24 hours post dose on Days 1 and 10
|
Area Under the Plasma Concentration-Time Curve (AUCtau)
Time Frame: Pre-dose up to 24 hours post dose on Days 1 and 10
|
Pre-dose up to 24 hours post dose on Days 1 and 10
|
Time of Peak Plasma Concentration (Tmax) of IX-01
Time Frame: Pre-dose to 24 hours post dose on Days 1 and 10
|
Pre-dose to 24 hours post dose on Days 1 and 10
|
Elimination Half Life (t1/2) of IX-01
Time Frame: Pre-dose up to 96 hours post dose on Day 10
|
Pre-dose up to 96 hours post dose on Day 10
|
Accumulation Ratio (Racc) of IX-01 based on AUCtau
Time Frame: Pre-dose up to 24 hours post dose on Day 10
|
Pre-dose up to 24 hours post dose on Day 10
|
Accumulation Ratio (Racc) of IX-01 based on Cmax
Time Frame: Pre-dose up to 24 hours post dose on Days 1 and 10
|
Pre-dose up to 24 hours post dose on Days 1 and 10
|
Area Under the Concentration-Time Curve (AUCt) from Zero to the Time of Last Quantifiable Concentration (AUC(0-t)) of IX-01
Time Frame: Pre-dose to 96 hours post dose on Day 10
|
Pre-dose to 96 hours post dose on Day 10
|
Minimum Observed Concentration (Ctrough) of IX-01
Time Frame: Pre-dose on Days 2 to 10
|
Pre-dose on Days 2 to 10
|
Elimination Rate Constant (Kel) of IX-01
Time Frame: Pre-dose up to 96 hours post dose on Day 10
|
Pre-dose up to 96 hours post dose on Day 10
|
Apparent Clearance of IX-01
Time Frame: Pre-dose up to 24 hours post dose on Day 10
|
Pre-dose up to 24 hours post dose on Day 10
|
Apparent Volume of Distribution During the Terminal Phase of IX-01
Time Frame: Pre-dose up to 96 hours post dose on Day 10
|
Pre-dose up to 96 hours post dose on Day 10
|
Urine 6-β-hydroxycortisol/cortisol Ratio
Time Frame: Pre-dose on Day 1 and Day 10
|
Pre-dose on Day 1 and Day 10
|
IX-01 Concentration and Amount Secreted in Semen
Time Frame: Between 2 and 4 hours after dosing, on Day 9
|
Between 2 and 4 hours after dosing, on Day 9
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Email: Ixchelsis@Choruspharma.com, Ixchelsis Limited
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2013
Primary Completion (Actual)
March 1, 2014
Study Completion (Actual)
March 1, 2014
Study Registration Dates
First Submitted
November 19, 2013
First Submitted That Met QC Criteria
November 19, 2013
First Posted (Estimate)
November 25, 2013
Study Record Updates
Last Update Posted (Estimate)
September 3, 2014
Last Update Submitted That Met QC Criteria
September 2, 2014
Last Verified
September 1, 2014
More Information
Terms related to this study
Other Study ID Numbers
- IX-0101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Participants
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
Insmed IncorporatedRecruitingHealthy ParticipantsUnited States
-
Aeovian Pharmaceuticals, Inc.RecruitingHealthy ParticipantsAustralia
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRecruitingHealthy ParticipantsChina
-
CelgeneNot yet recruitingHealthy ParticipantsUnited States
-
Bristol-Myers SquibbRecruiting
-
AstraZenecaParexelRecruiting
-
ProMis Neurosciences, IncRecruiting
-
Novo Nordisk A/SRecruitingHealthy ParticipantsCanada
-
Novo Nordisk A/SRecruiting
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States